USFDA conducts routine cGMP inspection at manufacturing facility of Cipla’s arm

03 May 2023 Evaluate

The United States Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc., wholly owned subsidiary of Cipla, located in Fall River, Massachusetts, USA, from April 24, 2023 to May 1, 2023. The inspection concluded with zero Form 483 observations.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1342.20 15.90 (1.20%)
25-Feb-2026 13:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1758.25
Dr. Reddys Lab 1304.50
Cipla 1342.20
Zydus Lifesciences 915.60
Lupin 2290.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×